RestorixHealth Announces 2025 Center Recognition Awards Program Recipients RestorixHealth, the nation’s leading wound care solutions company, is pleased to announce the wound and hyperbaric center recipients of their Center Recognition Awards program for the awards period July-December 2025. These prestigious…
VB Spine Announces Intent to Acquire Exclusive Rights to Augmedics’ Spine Platform VB Spine LLC the largest privately held spine company, today announced it has entered into a definitive agreement to acquire exclusive rights to the xvision Spine System® (xvision)…
Europe Oncology Genomics Tracker Captures Oncologist Perspectives Across Major European Markets – Data Report by DeciBio Consulting LLC A new survey-based Genomics Tracker focused on the EU-5 (France, Germany, Italy, Spain, and the United Kingdom) by DeciBio Consulting LLC provides updated insight…
LocumTenens.com Wins ClearlyRated’s 2026 Best of Staffing Client and Talent Awards for Service Excellence LocumTenens.com, a pioneer in healthcare staffing solutions, announced today that it has won ClearlyRated’s Best of Staffing® Awards in both the Client and Talent categories. Marking the organization’s 13th consecutive…
Worldwide Clinical Trials Completes Acquisition of Catalyst Clinical Research Worldwide Clinical Trials a global contract research organization (CRO), has completed its acquisition of Catalyst Clinical Research, LCC (“Catalyst”) – a specialized oncology CRO and scalable functional service provider (FSP). This strategic transaction creates a…
New ECCO data show subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control after drug holiday Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), showing that subcutaneous (SC) infliximab…
MEDIPOST Inc. Submits IND Amendment With U.S. Food and Drug Administration to Initiate Phase III Trial MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, announced today that it has filed an…
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia Alto Neuroscience, Inc. a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the…
Veradigm Brings Patient Voice to Healthcare Research with New Real-World Data Survey Solution Veradigm a leading provider of clinical and revenue cycle solutions for independent practices, today announced a new patient‑reported outcomes (PRO) survey capability that brings the patient voice directly…
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates Anebulo Pharmaceuticals, Inc. a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the…
Encora Therapeutics Receives FDA 510(k) Clearance for Encora X1™, a Breakthrough Wearable Device for Essential Tremor Encora Therapeutics, a leader in non-invasive neuromodulation technology, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the…
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting KalVista Pharmaceuticals, Inc. today announced the acceptance of three abstracts for presentation at the 2026 American Academy of Allergy, Asthma & Immunology…